and induced apoptosis and cell cycle arrest at concentrations equivalent to or lower than the parent compound Largazole. Using IV bolus delivery at 5 mg/kg, two compartmental pharmacokinetic modeling on the peptide isostere analog of Largazole indicated improved pharmacokinetic parameters. In an A549 non-small cell lung carcinoma xenograft model using a dosage of 5 mg/kg administered intraperitoneally every other day, Largazole, Largazole thiol, and Largazole peptide isostere demonstrated tumor growth inhibition (TGI %) of 32, 44, and 66 %, respectively. Largazole peptide isostere treatment was statistically superior to control (p = 0.002) and to Largazole (p = 0.006). Surprisingly, tumor growth inhibition was not observed with the potent pyridyl-based analogs. Conclusions These results establish that replacing the depsipeptide linkage in Largazole with an amide may impart pharmacokinetic and therapeutic advantage and that alternative prodrug forms of Largazole are feasible.
Introduction
The interest in histone deacetylase inhibitors (HDACi) as therapeutic agents in oncology has grown rapidly over the previous 10 years. Hundreds of clinical trials have been conducted with HDACi, primarily in oncological settings as a single agent or in combination therapy with more established therapeutic regimens. The successes of HDACi in clinical trials have been varied, with some studies showing little benefit, while the HDACi romidepsin (Istodax,HDACi can be structurally classified broadly into five classes: hydroxamates, benzamides, cyclic peptides, shorty chain fatty acids, and the recently characterized trifluoromethyloxadiazoles (TFMO) [4, 5] . The vast majority of clinical development to date has focused on hydroxamate class HDACi. The hydroxamates are highlighted by the FDA-approved vorinostat (Zolinza, SAHA) and the clinically advanced panobinostat (LBH-589) currently in phase III development in combination with bortezomib-dexamethasone in patients with relapsed multiple myeloma [6] [7] [8] . Hydroxamates are considered pan-HDACi, inhibiting class I and class IIa/b HDACs at therapeutic levels. Recently, however, the concept of pan-HDACi has been thrown into question and the frequently reported potent inhibitory activity to class IIa HDACs is likely an artifact of commonly used substrates used to determine potency [9] . Benzamide class HDACi are generally more selective and only inhibit class I HDACs at therapeutic levels, but are generally less potent than hydroxamate HDACi [10] . The most clinically relevant and advanced benzamide is entinostat (MS-275) currently entering phase III development for estrogen receptor-positive advanced breast cancer in combination with exemestane. The TFMO class is a new addition to the HDACi family of compounds with an inhibitory profile that is reportedly restricted to class IIa HDACs, the first inhibitors convincingly shown to target this class of deacetylases. The final two classes of HDACi are the short chain fatty acids such as butyrate and valproate and the cyclic depsipeptide class of HDACi. The cyclic depsipeptide HDACi consist largely of natural products including romidepsin, spiruchostatins, and the recently discovered marine HDACi Largazole.
Largazole, isolated via bioactive fractionation from the marine cyanobacteria species Symploca by Leusch et al., was shown to have substantial antineoplastic activity [11] . Subsequent work by Luesch and others revealed that the new compound was indeed a potent class I-selective HDACi, leading to a flurry of synthetic activity on this potentially clinically important natural product [12] [13] [14] . Largazole contains a 3-hydroxy-7-mercaptohept-4-enoic acid moiety common to several other macrocyclic depsipeptide natural products including FK228, FR901375, and the spiruchostatins. As with the other depsipeptide-based HDACi's, Largazole is a prodrug, requiring in vivo cleavage of the octanoyl residue to reveal the active thiol form of the compound that acts to chelate the Zn 2+ ion found in the active site of the zinc-dependent HDACs. Significantly, unlike romidepsin where the prodrug is activated via reduction of a disulfide, the prodrug form of Largazole is liberated via facile lipase/esterase cleavage of the thioester. A second unique feature of Largazole is the macrocycle capping group that contains a thiazoline-thiazole unit that imparts excellent binding geometry for class I HDAC recognition [15] .
In the present study, we have utilized novel macrocycle scaffold replacements of the parent compound Largazole and a pyridyl disulfide-based prodrug compound to investigate the potential to produce a lead-optimized HDACi that would improve pharmacokinetics and in vivo and in vitro performance. Compounds included in this study are the previously reported synthetic Largazole analogs that have undergone isosteric oxygen to nitrogen replacement to insert a peptide linkage in place of the depsipeptide, pyridyl-thiazole substitutions, and an alternative prodrug form [16, 17] .
Materials and methods
Cell culture and growth inhibition assays All cells were purchased from the American Type Culture Collection (Manassas, VA) and cultured in Dulbecco's modified Eagle's medium (DMEM) (Lonza, Walkersville, MD) supplemented with 10 % fetal bovine serum (Atlas Biologicals, Fort Collins, CO) and supplemented with amino acids (nonessential amino acids Cellgro/Corning Manassas VA) and maintained at sub-confluent densities at 37 °C, humidified air, and 5 % CO 2 . Cells were seeded in 96-well clear bottom NUNC plates at 3.0 × 10 3 (A549, HTC-116, HT-29), 6.0 × 10 3 (SW620), and 2.0 × 10 3 (MiaPaCa), and allowed to adhere overnight (16 h). Media were replaced just prior to addition of Largazole or Largazole analogs prepared as 2 mM stocks in DMSO. Dilutions of stocks were made to cover the range of 4 pM-40 μM. Cells were incubated in the presence of drug for 48 h. After 48 h, 10 μL/well of sterile resazurin (Sigma Aldrich St. Louis MO) was added (200 μg/mL in PBS) and incubated at 37 °C for 2-3 h followed by fluorescence measurements at (530ex/590em) on a Synergy HT plate reader (Biotek, Winooski, VT). Relative viable cell number was standardized to untreated cells, and cell viability was assessed by calculating IC 50 by entering the data into Prism (GraphPad, La Jolla, CA) and performing three-parameter nonlinear curve fitting. All values are the average of at least three independent experiments.
Isolated HDAC inhibition
The method used for determination of IC50's to specific HDAC proteins is as reported in [12] . In brief, purified fulllength HDAC proteins HDAC1, HDAC2, HDAC3/NCor2, and HDAC6 0.6 (BPS Biosciences) were incubated with a commercially available fluorophore-conjugated substrate at a concentration equivalent to the substrate Km (Upstate 17-372; 6 µM for HDAC1, 3 µM for HDAC2, 6 µM for HDAC3/NCoR2, and 20 µM for HDAC6) in the presence of varying concentrations of test article.
Apoptosis by annexin V/propidium iodide Cells were plated in 6-well plates at a density of 2.5 × 10 5 per well in 2 mL DMEM in 10 % fetal bovine serum and allowed to adhere to the plate overnight. Media were aspirated, the cell monolayer was washed once with PBS containing penicillin and streptomycin (0.1 %), and fresh DMEM was added to wells. Largazole or Largazole analogs were added at the concentrations indicated in the corresponding figure, and cells were incubated for 24 h. Media were collected into 15-mL conical tubes and wells washed once with PBS. Adherent cells were harvested by typsin/ EDTA digestion and added to the tube. All cells were then pelleted via centrifugation at 1,200×g. Cell pellets were washed two times with PBS and re-suspended in 100 μL 1× binding buffer and 2.5 μL of annexin V (V450, BD Pharmingen™, San Jose, CA). Cells were incubated at room temperature for 15 min in the absence of light, and 1× binding buffer was added to a final volume of 400 μL followed by the addition of 5 μL of propidium iodide (50 μg/mL in PBS, Sigma Aldrich, St. Louis, MO). Cells were analyzed in <1 h on a CyAn ADP (Dako, Carpinteria, CA) flow cytometer along with the unstained and singlestained cells to determine appropriate gating. All data were analyzed by FlowJo software (Ashland, OR). Micrograph images of the time-course experiment were acquired under at 10× magnification using the EVOS ® Cell Imaging System (LifeTech, Carlsbad, CA).
Cell cycle distribution
Asynchronous cells were treated as above and collected as described for the annexin V assay above. Cells were fixed by adding drop-wise 1 mL of ice cold 70 % ethanol and stored at −20 °C until assay. Cells were pelleted, washed once with PBS. Cell pellets were re-suspended in μL PBS and 200 μL extraction buffer (0.2 M Na 2 HPO 4 , 0.1 M Citrate) followed by the addition of 500 μL of propidium iodide (125 Worthington units/mL RNAase A and 50 μg/ mL propidium iodide, Sigma). The cell suspension was incubated at 37 °C for 30 min followed by data collection via flow cytometry as above and analysis by FlowJo software using the Dean-Jett-Fox algorithm.
Western blot
Cells were plated in six well plates and allowed to adhere overnight. The next day, Largazole and Largazole analogs were added to the indicated concentrations and incubated for 24 h. Cells were lysed in 1× M-PER buffer (Pierce Chemical, Rockford, IL) containing HALT protease inhibitor cocktail (Pierce) and 0.1 mM phenylmethylsulfonyl fluoride; benzonase (EMD Millipore) was added to samples as needed to digest nucleic acid. The protein concentration was measured with the BCA Protein Assay kit (Pierce). Lysates containing equal amounts of protein were separated on NuPage bis-tris precast gels 4-12 % (Life Technologies, Grand Island, NY), transferred to polyvinylidene difluoride membranes, blocked with SuperBlock (Pierce), and probed with antibodies. Antiacetyl histone H3 and H4 antibodies were purchased from Millipore (Ac-H3, 06-599; Ac-H4, 06-598). Primary antibodies were diluted 1/1,000 in 5 mL SuperBlock and incubated with membranes containing transferred proteins overnight with gentle agitation at 4 °C. After incubation with primary antibody, blots were washed 3 × 5 min in tris-buffered saline plus Tween-20 (TBST). The secondary antibody (goat anti-rabbit HRP conjugated, Pierce) was diluted 1/20,000 in SuperBlock and incubated at 4 °C with gentle agitation for at least 2 h followed by TBST wash as above. Detection of signal was performed with the SuperSignal Pico West Substrate (Pierce) per manufacturers' instructions, and image was acquired using a Molecular Imager ® system equipped with a CCD camera (BioRad, Redman WA). Tumor lysates were generated as above with the exception that 50-100 mg of tumor tissue was placed into tubes, and lysates were generated using a Bullet Blender ® (Next Advance, Inc. Averill Park, NY).
Ki-67 automated IHC
Immunohistochemical staining was performed using standard techniques on an automated stainer (Autostainer Link 48; Dako; Carpenteria, CA). Briefly, 4-µm histosections were cut and mounted on positively charged slides. The sections were deparaffinized and then rehydrated with descending alcohol concentrations to buffer. Heat-induced epitope retrieval with EDTA buffer (pH 8.0) for 20 min was followed by endogenous peroxidase blocking with 3 % hydrogen peroxide and incubation with the primary antibody at room temperature for 30 min. The primary antibody used was a monoclonal mouse antihuman Ki-67 antibody at a dilution of 1:50 (M7240; Dako; Carpenteria, CA). A prediluted, universal secondary antibody and DAB-based detection kit (K8023; Dako; Carpenteria, CA) were utilized to detect the immunoreactive complexes. The slides then were counterstained with Mayer's hematoxylin. Images for IHC analysis were acquired at 20× magnification using an Olympus BX40 microscope (Tokyo, Japan), a ProgRes Speed XT Core5 camera equipped with ProgRes Capture Pro 2.7 software (Jenoptik, Germany).
Animals, A549 xenograft, pharmacodynamic dosing, and IV bolus pharmacokinetic analysis All mice were housed five animals per cage in a controlled low-pathogen environment with each group containing 1 3 eight animals. All animal handling and marking were done to minimize pain, suffering, and distress as defined by the procedures and policies of Colorado State University animal handling and as detailed in the approved IACUC protocol 12-3592A. Female athymic NCr-nu/nu nude mice 6-8 weeks of age were purchased from NCI (Fredrick, MD) and acclimated. Tumors were established by subcutaneous injection of 1 × 10 7 A549 cells on the left rear flank in 100 μL serum-free DMEM mixed 1:1 with Matrigel (BD Biosciences, San Jose, CA). Tumor dimensions were measured every other day using a Vernier caliper. Tumor volumes were calculated by using the formula 0.5 (W 2 × L) where W = width and L = length (L) with the length being taken as the longest tumor dimension, and tumor growth inhibition was determined by (TV control day x − TV initial ) − (TV treatment day x)/(TV control day x − TV initial ), where TV is the respective tumor volume of control, treatment, or initial measurement. Animals were killed when tumor volumes reached ≥1,000 mm 3 . Tumor volumes and overall days to endpoint were entered into Prism, and statistical significance was determined by pair-wise Mann-Whitney U test and Kaplan-Meier analysis. All compounds were prepared fresh on the day of treatment in DMSO, and mice were treated via intraperitoneal injection every other day for 13 days at 5 mg/kg.
To show pharmacodynamic response to compound treatment, animals that were at or near endpoint at day 35 of the study (last study day) were treated for 4 consecutive days with 5 mg/kg of test articles as above. On day 4, animals were killed and organs and tumors were collected. Tumors were sectioned and placed into formalin for immunohistochemistry or snap frozen for Western blot analysis.
For pharmacokinetic analysis, female NIH Swiss mice were dosed with 5 mg/kg Largazole or Largazole peptide isostere that were prepared in 75:25 (DMSO:USP sterile saline for injection) and injected via tail vein in a volume of 50 μL per 25 g and euthanized at the indicated time points (n = 3 per time point). Whole blood was collected by centrifugation after cardiac venipuncture into heparinized syringes. Whole blood was collected from mice of similar age and strain and used to make a standard curve ranging from 0 to 20,000 ng/mL along with quality control (QC) samples for determination of precision and accuracy. Samples (50 μL) were spiked with 5 μL internal standard (trazodone at 250 pg/mL), followed with the addition of 5 μL of 75 mM dithiothreitol (DDT solution was prepared by first dissolving in Milli-Q water, then 1 mL of 0.1 N NaOH was added, and finally 3.75 mL of 70/30 EtOH/Milli-Q was added). Samples were vortex mixed for 10 min, centrifuged for 5 min at 18,000×g. After allowing samples to stand for 15 min, 1 mL of ethyl acetate was added, vortex mixed for 10 min, and again centrifuged for 10 min at 18,000×g. Nine hundred (900) μL of the organic layer was transferred to empty 2-mL micro-centrifuge tubes and was placed in SpeedVac (Savant AES 1000-120, Thermo Scientific, Asheville, NC) for approximately 1 h. Samples were reconstituted in 100 μL of 80/20: acetonitrile with 0.1 % acetic acid/10 mM ammonium acetate with 0.1 % acetic acid in Milli-Q, vortexed for 10 min, and centrifuged for 5 min at 18,000×g. Samples were transferred to HPLC vials and analyzed by mass spectrometry.
Mass spectrometry
Positive ion electrospray ionization (ESI) mass spectra were obtained with a MDS Sciex 3200 Q-TRAP triple quadrupole mass spectrometer (Applied Biosystems, Inc., Foster City, CA) with a turbo ionspray source interfaced to a Shimadzu HPLC system (Columbia, MD). Samples were chromatographed with an XBridge Phenyl, 5 µm, 4.6 × 50 mm column (Waters Corporation, Milford, MA) protected by a C18 guard cartridge, 4.0 × 2.0 mm (Phenomenex, Torrance, CA). An LC gradient was employed with mobile phase A consisting of 10 mM ammonium acetate with 0.1 % acetic acid and mobile phase B consisting of acetonitrile with 0.1 % acetic acid. Chromatographic resolution was achieved by increasing mobile phase B linearly from 30 to 98 % from 1 to 3 min, maintaining at 98 % from 3 to 5 min, decreasing linearly from 98 to 30 % from 5 to 6 min, followed by re-equilibration of the column at 30 % mobile phase B from 6 to 7 min. The LC flow rate was 1 mL/ min, the sample injection volume was 20 µL, and the analysis run time was 7 min.
The optimized mass spectrometer settings for Largazole and Largazole thiol are provided in Table 1 . The source conditions were optimized as follows: turbo ionspray Quantification of Largazole and Largazole thiol was based on the prepared standard curve of each respective compound using the ratio of either compounds summed peak areas to trazodone peak area and 1/x 2 weighting of linear regression. Parameters for the assessment of assay performance were calculated as follows: , where A and B are the intercepts for the rate constants of each phase. Non-compartmental parameters calculated included total body clearance (CL), volume of distribution at steady state (Vss), mean residence time (MRT), area-underthe-curve from time zero to infinity (AUC 0-inf ) calculated using the linear trapezoidal method with linear interpolation, and area-under-the-first-moment-curve (AUMC). For purposes of comparison between drugs, actual plasma drug concentrations were utilized to generate time-concentration curves and these compared using 2-way ANOVA.
Results
Macrocycle substitutions in Largazole are potent inhibitors of tumor cell growth and class I HDACs Several Largazole analogs as shown in Fig. 1 were screened against colon (HT-116, HT-29, SW620), non-small cell lung carcinoma (A549), and pancreatic (MiaPaCa) cancer cell lines to determine growth inhibitory properties. As shown in Table 2 , all compounds tested inhibited growth with IC 50 s in the mid-to low-nanomolar to high-picomolar range. The pyridyl analog depsipeptide had a trend toward higher potency as measured by IC 50 relative to the parent compound Largazole in all cell lines tested. Peptide isosteric replacement of the depsipeptide linkage was tolerable; however, a loss of potency was observed (threefold to tenfold). The Largazole peptide isostere had levels of potency comparable to the pyridyl analog peptide isostere congener.
Analysis of IC 50 inhibitory properties of Largazole and Largazole analogs against class I HDACs (HDAC 1,2,3) and the class IIb HDAC 6 is shown in Table 3 . Largazole and Largazole analogs were all more potent than the hydroxamate-based HDACi vorinostat (SAHA) with Largazole, the pyridyl analog depsipeptide, and Largazole peptide isostere compounds having a potency that is at least 40-to 50-fold greater than vorinostat to class I HDACs. Moreover, selectivity to class I HDACs relative to HDAC 6 is ~30-to 160-fold for the pyridyl analog depsipeptide, while the Largazole peptide isostere has a selectivity to class I HDACs that is ~170-to 340-fold relative to HDAC 6.
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Induction of apoptosis by Largazole analogs
To further explore the potency of substituted macrocycle analogs of Largazole and their ability to induce an apoptotic response, annexin V (AV) and propidium iodide (PI) staining was done in A549 cell lines at 24, 48, and 72 h. As shown in Fig. 2 , all the compounds induced apoptosis as measured by annexin V staining in the low-to mid-nanomolar range after 24 h of drug exposure. Overall potency of the compounds followed the general trends observed in growth inhibition experiments, with the peptide isostere replacements requiring higher concentrations to achieve cell populations showing late (AV+/PI+) and early (AV+/PI−) apoptosis. A progression of apoptosis was shown in all compounds with the exception of the pyridyl analog peptide isostere. Notably, a sharp increase in the number of apoptotic cells was seen from 48 to 72 h in the alternative prodrug Largazole analog, the pyridyl analog pyridyl disulfide. As shown in the micrographs above the raw cytometry data, striking cell morphology changes (spikes and blebs) that are hallmarks of apoptosis were evident 24 h post-treatment. Similar results were achieved in the SW620 and MIA PaCa cell lines (data not shown).
Cell cycle arrest by Largazole and analogs
To evaluate changes in cell cycle distribution following treatment with Largazole and Largazole analogs, A549 (non-small cell lung carcinoma) cells were treated with the indicated concentrations of Largazole or analogs as shown in Fig. 3 for 24 h followed by propidium iodide staining and flow cytometry for cell cycle analysis. Substantial G1 arrest was noted with all compounds evaluated, with a depletion of S-phase cells.
Method development and pharmacokinetic modeling
Due to the rapid processing in vivo of the thioester prodrug structure of Largazole to the active thiol form, developing a bioanalytical method to analyze Largazole and prodrug proved challenging. Initial attempts to trap the active thiol with N-ethylmaleimide yielded fair results; however, poor precision and accuracy of measuring the prodrug in matrix led to the abandonment of this approach. In our method development studies, it was noted that processing of the prodrug was quite rapid and was <LLOQ after 10 min of room temperature incubation in plasma or whole blood. Due to the risk of spurious results being generated during the processing of early time point samples, our solution was to focus solely on the active thiol form of the drug. This was accomplished by the addition of a pre-extraction incubation in matrix to yield the thiol form of the drugs.
The second major obstacle encountered was the fact that the thiol form of Largazole forms adducts with blood components, presumably through thiol-disulfide exchange reactions. While developing the whole blood extraction protocol, it was noted the addition of DTT improved recoveries of Largazole thiol by at least 30 %; therefore, the final method included a DTT reduction step to liberate, at least partially, adducted Largazole thiol. While a full method validation was beyond the scope of our objectives, the range of the method was established as 1-1,000 ng/ mL for both Largazole thiol and Largazole peptide isostere thiol (data not shown). Samples expected to fall above the range were diluted 1:4 to ensure sufficient precision and accuracy. Quality control (QC) samples processed during the LC-MS/MS analysis of the pharmacokinetic samples passed typical accuracy and precision acceptance criteria for a bioanalytical method, and all QC samples were within ±15 % the nominal value (data not shown).
As previously reported, the rationale for replacing the depsipeptide ester linkage present in Largazole with a peptide isostere linkage was to impart improved hydrolytic stability. To investigate if indeed the Largazole peptide isostere has improved pharmacokinetic properties relative to the parent natural product Largazole, female NIH Swiss mice were dosed via tail vein injection with 5 mg/kg Largazole or Largazole peptide isostere. Blood was collected at 5, 15, 30, 60, 120, and 240 min for analysis by LC-MS/ MS. To model both the distribution phase and the elimination phase of Largazole and Largazole peptide isostere, a two-compartment model was chosen.
Upon inspection of the parameters of the two-compartment model shown in Table 4 , it is clear that the two compounds' parameter estimates were quite similar. The two compounds had nearly identical distribution as signified by the similarities in Vss as well as the volumes of the central (V1) and peripheral (V2) compartments (data not shown). Direct comparison of the raw plasma timeconcentration curves between Largazole and Largazole peptide isostere demonstrated a significant difference (p = 0.0121, Fig. S1 ). The notable difference in drug exposure (AUC) observed between the two compounds, with the Largazole peptide isostere showing an ~30 % increase (AUC %CV = 13, %CV = 9 for Largazole and Largazole peptide isostere, respectively), is presumably due to the slower drug elimination or stability. This increased drug exposure is manifested in the longer elimination half-life (Beta HL) as well as the decreased clearance (CL) and a longer mean residence time (MRT). Thus, Largazole and Largazole peptide isostere showed similar pharmacokinetic properties both with regard to drug distribution and drug elimination, with the modest improvement in drug exposure unlikely to fully explain the difference in vivo antitumor efficacy.
Tumor concentrations of the compounds were measured 3 h after four consecutive days of treatment (pharmacodynamics, Fig. 5 ), and were similar (215 ± 24 and 141 ± 32 ng/g) for the Largazole and Largazole peptide isostere, respectively.
A549 xenograft model
To investigate the in vivo efficacy of Largazole and Largazole analogs, A549 non-small cell lung carcinoma cells were injected subcutaneously into the rear flank of athymic nude mice. Largazole or Largazole analogs were administered i.p. every other day at 5 mg/kg for 13 days (seven total treatments). This dosage and schedule were chosen based on previously published values and to potentiate any pharmacokinetic advantage that may exist in Largazole peptide isostere analogs [18] . As shown in Fig. 4a , tumor growth rate was slower in Largazole, Largazole thiol, and Largazole peptide isostere-treated mice compared with vehicle-treated controls. The results of the pair-wise, two-tailed Mann-Whitney test shown in Table 5 indicate that Largazole thiol and Largazole peptide isostere-treated mice had tumor growth rate reductions that were statistically different from the control group (p = 0.040 and p = 0.002, respectively). Moreover, the Largazole peptide isostere was also statistically different from both Largazole and Largazole thiol (p = 0.006 and p = 0.023, respectively). Largazole was not statistically different from the control, likely due to the high standard deviation of tumor volumes within the group; however, tumor growth inhibition (TGI %) was 32 % of control. The TGI % for the Largazole thiol-treated group was 42 and 66 % for Largazole peptide isostere group relative to the control 10 days after the last treatment (day 23) . Surprisingly, neither pyridyl-substituted Largazole analog showed tumor growth inhibition in the A549 model using this every other day dosing regimen (data not shown), in spite of the high potency in cell-based assays for the pyridyl analog depsipeptide. The study was terminated at day 35 for humane reasons as no persistence of the treatment was observed. Animal body condition was robust for the Largazole peptide isostere group with minimal weight loss occurring. As is clear from the TGI % of Largazole thiol, the masked prodrug is fully dispensable for antitumor activity, a result that is not unexpected based on the rapid cleavage of the thioester-acyl tail in blood or plasma. On the other hand, mice in the Largazole thiol group experienced moderate weight loss (~2 %) and one fatality occurred indicating that at least some toxicity may occur from use of the free thiol by this route of administration.
Pharmacodynamics, Ki-67 IHC, and dose response in vitro To show engagement of HDAC therapeutic target in vivo, previously treated xenograft, animals were selected that were at endpoint (tumor volume 900-1,000 mm 3 and >14 days since last dose) and were treated on four consecutive days with 5 mg/kg of Largazole compounds i.p. as discussed above. On the last day of dosing, animals were killed 3 h post-administration, and tumors, blood, and organs were collected. As shown in Fig. 5a , the Ki-67 marker for proliferation shows markedly reduced staining for Ki-67 in the Largazole, pyridyl analog depsipeptide, and to a lesser degree in the Largazole peptide isostere tumor sections relative to the control. Only a slight difference in staining frequency/intensity was observed with the pyridyl analog peptide isostere and the pyridyl analog pyridyl disulfide when compared to the control. As presented in Fig. 5b , an increase in acetylated H3 and H4 was observed in all samples relative to the control by western blot. Finally to demonstrate dose dependency of Largazole or Largazole analog treatment, A549 cells were treated with 10-1,000 nM for 24 h. All compounds generated an increase in acetylated H3 and H4 in a dose-dependent fashion with levels of acetylation that paralleled the observed potency of the compounds in vitro (Fig. 5c ).
Discussion
The work presented herein has shown that modifications of the macrocycle and/or alternative prodrug structure of the highly potent class I-selective marine natural product HDACi Largazole can be accomplished without loss of activity. Indeed, the results of this study and our previous work reveal that desirable properties can be designed from the Largazole scaffold to achieve compounds that have improved clinical properties such as potency, class selectivity, and pharmacokinetics [16, 17, 19] . As shown in Table 3 above, the Largazole peptide isostere is an exceptionally class I-selective HDACi relative to the parent depsipeptide natural product Largazole and may have unique clinical utility based on its highly selective HDACi profile.
A trend toward in vitro potency improvement is suggested by decreased cellular growth as shown by IC 50 s, induction of apoptosis as assessed by AV/PI staining, and cell cycle arrest for the pyridyl analog depsipeptide. The potency of the pyridyl analog depsipeptide is at least that observed with the clinically advanced hydroxamate HDACi panobinostat in the cell lines tested here [7, 20] . Much to our surprise, the improved in vitro potency of this analog did not manifest in improved efficacy in vivo. The reason for this result is unknown at present and may be a result of poor pharmacokinetic properties or high plasma protein binding with the pyridyl analog series. However, increasing dosing frequency to a daily regimen of the pyridyl analog depsipeptide did nearly abrogate Ki-67 IHC staining, indicating a potential for better efficacy in future studies with higher dose levels or more frequent dosing.
It is interesting to note that, despite similar inhibitory effects against the different HDAC isoforms evaluated, the Largazole pyridyl analog depsipeptide appeared to have considerably more in vitro growth inhibitory activity than the parent Largazole compound. Although off-target effects cannot be ruled out, the increase in cytotoxic/cytostatic activity of the pyridyl depsipeptide compound is likely due to a combination of increased membrane permeability/cellular retention, enhanced activity in the context of native state protein-protein interactions, and potentially differential HDAC isoform selectivity for other isoforms not evaluated.
The replacement of the relatively labile ester linkage of the depsipeptide found in the parent compound as well as romidepsin (FK228) and spiruchostatin can be predicted to improve hydrolytic stability [21] . Indeed, the results of the two compartmental PK modeling suggest that this prediction held true in vivo. It is tempting to conclude that the modest improvements seen in clearance (CL) and AUC with the Largazole peptide isostere relative to the parent compound Largazole were the basis for the improved efficacy observed in the xenograft study. However, reduced plasma protein binding, reduced affinity for p-glycoprotein (Pgp), or decreased up-regulation of MDR1 may also play a role. Romidepsin is a substrate for Pgp, and its administration up-regulates MDR1 expression. These observations are considered major factors in acquired romidepsin resistance [22, 23] . The level of tumor growth suppression observed in this study compares very favorably with other published studies of HDACi in the A549 xenograft model, further supporting the potential clinical utility of Largazole and Largazole analogs [7, 24, 25] . In summary, we have presented preclinical results on induction of apoptosis, cell cycle arrest, tumor growth suppression, and demonstrated the potential to modify the parent compound Largazole to improve in vivo performance. Furthermore, this work has delineated the potential clinical importance of the marine HDACi Largazole and synthetic Largazole analogs that reveal the robust nature of the Largazole macrocycle scaffold to be used in future drug development programs. As we and others have shown, Largazole and its analogs are important clinical candidates and represent a promising new addition to the broad field of HDACi in clinical development.
